-transparent.png){kind=logo}
The efficacy of naproxen sodium (naproxen-Na) in dysmenorrhea has been established in two independent double-blind (placebo-controlled) studies. An initial dose of 550 mg. of naproxen-Na was followed by 275 mg. every six hours for a maximum of five days. Twenty patients were included in Study I (10 treated with naproxen-Na) and 23 patients in Study II (12 treated with naproxen-Na). Each patient received the medication during four dysmenorrheic episodes. Thus, a total of 172 treatment courses could be evaluated. A variety of efficacy criteria were measured: frequency of pill intake, changes in pain intensity, the degree of relief achieved by the medication, and need for additional analgesics. In both studies naproxen-Na was demonstrated to be superior to the placebo treatment with high statistical significance in each of these parameters.
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
September 1977,
Obstetrical & gynecological survey,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
January 1978,
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
January 1989,
Acta obstetricia et gynecologica Scandinavica,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
September 1985,
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
August 1988,
The Journal of rheumatology,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
January 2005,
Journal of general internal medicine,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
May 1980,
Prostaglandins,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
January 1983,
Acta obstetricia et gynecologica Scandinavica. Supplement,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
November 1964,
Journal of the Medical Association of the State of Alabama,
M R Henzl, and
V Buttram, and
E J Segre, and
S Bessler
January 1990,
Clinical therapeutics,
